Announcement:
Appointment of Drug Hunter Advisory Board Member: Gary Yeung, CFA
Drug Hunter is pleased to introduce a new member of our Advisory Board, Gary Yeung.
Gary Yeung is a life science executive (President, COO, CFO, and CBO), board member, advisor, and investor with extensive strategy, finance, business development, and operations experience in forming and building biotech companies and developing novel therapies.
Gary has raised over $570M ($370M as CFO and $200M as an advisor and board member) while forming and building multiple successful biotech companies: Xilis, Erasca (NASDAQ: ERAS), NiKang, Guardant Health (NASDAQ: GH), and Annexon Biosciences (NASDAQ: ANNX). He has led organizations engaged in filing 42 INDs, and led teams that launched multiple FDA-approved treatments at Genentech.
“Gary is a thoughtful life sciences leader and who has a long track record of helping organizations execute their visions,” says Drug Hunter founder Dennis Hu. “We are fortunate to have Gary’s insights as we build the Drug Hunter organization to serve our community.”
Earlier in his career, Gary worked in management consulting at McKinsey and operations leadership at GE. He holds a B.S. in Chemical Engineering from the University of California, Berkeley and an MBA from University of California, Los Angeles. He is a Chartered Financial Analyst (CFA).
About Drug Hunter
Drug Hunter is a science-first digital publication for pharmaceutical leaders, focused on saving readers time, keeping professionals up-to-date, and celebrating the work done in the technology-rich biotech and pharmaceutical industries.
